VIOLIN: Vaccine Investigation and Online Information Network

Vaccine Detail

Nanocovax

Vaccine Information

Vaccine Name: Nanocovax
Target Pathogen: SARS-CoV-2
Target Disease: COVID-19
Manufacturer: Nanogen Pharmaceutical Biotechnology
Vaccine Ontology ID: VO_0005092
Type: Subunit vaccine
Status: Clinical trial
Host Species for Licensed Use: Human
Immunization Route: Intramuscular injection (i.m.)

Host Response

Hamster Response

Immune Response: A viral challenge study using the hamster model showed that Nanocovax protected the upper respiratory tract from SARS-CoV-2 infection. (Tran et. al 2021)
Side Effects: Nanocovax did not induce any adverse effects in mice (Mus musculus var. albino) and rats (Rattus norvegicus). (Tran et. al 2021)

References

Tran et. al 2021: Thi Nhu Mai Tran, Bruce Pearson May, Trong Thuan Ung, Mai Khoi Nguyen, Thi Thuy Trang Nguyen, Van Long Dinh, Chinh Chung Doan 1, The Vinh Tran 1, Hiep Khong 1, Thi Thanh Truc Nguyen 1, Hoang Quoc Huy Hua 1, Viet Anh Nguyen 1, Tan Phat Ha 1, Dang Luu Phan 1, Truong An Nguyen 1, Thi Ngoc Bui 1, Tieu My Tu 1, Thi Theo Nguyen 1, Thi Thuy Hang Le 1, Thi Lan Dong 1, Trong Hieu Huynh 1, Phien Huong Ho 1, Nguyen Thanh Thao Le 1, Cong Thao Truong 1, Hoang Phi Pham 1, Cong Y Luong 1, Nie Lim Y 1, Minh Ngoc Cao 1, Duy Khanh Nguyen 1, Thi Thanh Le 2, Duc Cuong Vuong 2, Le Khanh Hang Nguyen 2, Minh Si Do 1. Preclinical Immune Response and Safety Evaluation of the Protein Subunit Vaccine Nanocovax for COVID-19. . 2021; ; . [PubMed: 34938290].